Specialist · Montreal, QC
CTI Life Sciences
Pre-clinical and clinical-stage biotech investing.
- Cheque
- $5M to $10M
- Role
- Can lead a round
- Pace
- Actively deploying
- Kind
- Specialist
- Based in
- Montreal, QC
- Vehicle size
- $100M
- Founded
- 2006
- Works in
- EN + FR
- Last deal seen
- February 2026
- Stages
- Seed, Series A, Series B and later
- Sectors
- Health and biotech
Their thesis, in full
Montreal biotech VC deploying its third fund (CTI LSF III, $100M CAD first close, 2021), backing pre-clinical and clinical-stage therapeutics across Canada, the US and Europe, often as lead and company builder, with roughly $345M CAD under management across three funds.
What they bring past the cheque
- Two decades of biotech investing
- Pre-clinical to clinical guidance
- North American syndicate network
- Lead investor capacity
- Therapeutic development expertise
Questions they usually ask
Have an answer ready for each one before the first call.
- What is your lead asset, and what does the next data readout need to show?
- How strong and defensible is the underlying intellectual property?
- What is the realistic partnering or exit path for your indication?
Follow-on
CTI Life Sciences Fund follows its therapeutics companies through clinical milestones and co-leads later rounds with specialist US and Canadian biotech investors. Follow-on conviction is tied to clinical data readouts.
Portfolio
Names they back, most notable first.
- Find TherapeuticsSeries A · 2026
- Kainova TherapeuticsSeries B · 2026
- Oligon Therapeutics2025
- Ability Pharma
- Aeovian Pharmaceuticals
- DalCor
- enGene
- Epitopea
- Glycomine
- Phenomic AI
- Profound Medical
- Thryv Therapeutics
Similar investors
Overlapping sectors and stages. Useful to build a list of 10 to 20 names for one round.
See how they fit your round
Set your stage, sector and amount once. Fractal App tells you if CTI Life Sciences can lead it, tracks every follow-up, and counts the days of silence. Free, no card.
Open in the app →